Browse Studies — Arctuva

Phase 2

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal…

Phase 2Sacituzumab TirumotecanRefractory Metastatic+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07511023

Phase 2

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combinat…

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Estimated

~$10 – $8,750

Stingray TherapeuticsNCT06589440

Phase 2

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patien…

Refractory Metastatic Colorectal Cancer

Estimated

~$10 – $8,750

Delcath Systems Inc.NCT06607458